{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:07:53Z","timestamp":1780582073518,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2785,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p>A 79\u2010year\u2010old Caucasian woman who had been taking alendronate 10 mg\/day for over 2 years to prevent osteoporosis reported hearing \u201cvoices in her head\u201d along with red\u2010colored visual disturbances. These auditory hallucinations and visual disturbances began shortly after her regimen was changed from alendronate 10 mg\/day to 70 mg once\/week. Assessment of causality using the Naranjo and Jones algorithms revealed a \u201cprobable\u201d and \u201chighly probable\u201d relationship, respectively, between this adverse drug event and the switch from daily to weekly alendronate therapy. Other bisphosphonates, such as etidronate and pamidronate, have caused both reversible and irreversible auditory, visual, and olfactory hallucinations beginning 2 hours\u20131 week after drug administration. The mechanism behind these adverse effects is unknown but is thought to be independent of calcium homeostasis. Clinicians should be aware of central nervous system toxicity as a rare but potential adverse effect associated with bisphosphonates.<\/jats:p>","DOI":"10.1592\/phco.24.8.799.36062","type":"journal-article","created":{"date-parts":[[2004,7,20]],"date-time":"2004-07-20T11:47:51Z","timestamp":1090324071000},"page":"799-802","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Alendronate\u2010Induced Auditory Hallucinations and Visual Disturbances"],"prefix":"10.1002","volume":"24","author":[{"given":"Craig I.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Perkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Merck and Co. Inc.Fosamax (alendronate) package insert. Whitehouse Station NJ;2003."},{"key":"e_1_2_1_3_2","unstructured":"Aventis Pharmaceuticals Inc.Actonel (risedronate) package insert. Kansas City MO;2003."},{"key":"e_1_2_1_4_2","unstructured":"Sanofi\u2010Synthelabo Inc.Skelid (tiludronate) package insert. New York NY;2002."},{"key":"e_1_2_1_5_2","unstructured":"Procter & Gamble Pharmaceuticals.Didronel (etidronate) package insert. Cincinnati OH;2003."},{"key":"e_1_2_1_6_2","unstructured":"Novartis Pharmaceuticals.Aredia (pamidronate) package insert. East Hanover NJ;2003."},{"key":"e_1_2_1_7_2","unstructured":"Novartis Pharmaceuticals.Zometa (zoledronic acid) package insert. East Hanover NJ;2003."},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2001.25426"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.10.1031"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1999.tb01599.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.7.927-d"},{"key":"e_1_2_1_12_2","first-page":"1105","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Schultz N.J.","year":"1993"},{"key":"e_1_2_1_13_2","first-page":"337","article-title":"Uveitis, an under\u2010recognized adverse effect of pamidronate: case report and literature review","volume":"67","author":"Rey J.","year":"2000","journal-title":"Joint Bone Spine"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.1022-a"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003727-198208000-00009"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.24.8.799.36062","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.24.8.799.36062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:51:52Z","timestamp":1761043912000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.24.8.799.36062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1592\/phco.24.8.799.36062"],"URL":"https:\/\/doi.org\/10.1592\/phco.24.8.799.36062","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}